CLINICAL TRIALS PROFILE FOR TROSPIUM CHLORIDE
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
All Clinical Trials for Trospium Chloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00465959 ↗ | Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease | Completed | Alkermes, Inc. | Phase 1/Phase 2 | 2007-04-01 | To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD |
| NCT00465959 ↗ | Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease | Completed | Endo Pharmaceuticals | Phase 1/Phase 2 | 2007-04-01 | To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD |
| NCT00800462 ↗ | Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity | Completed | Ontario Neurotrauma Foundation | Phase 4 | 2008-03-01 | This is a phase IV, double-blind, multicenter, randomized trial evaluating the efficacy and safety of two M3 receptors antagonists (Trospium Chloride and Darifenacin Hydrobromide) with one standard drug (Oxybutynin Chloride) for treatment of overactive bladder in individuals with spinal cord injury. |
| NCT00800462 ↗ | Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity | Completed | Toronto Rehabilitation Institute | Phase 4 | 2008-03-01 | This is a phase IV, double-blind, multicenter, randomized trial evaluating the efficacy and safety of two M3 receptors antagonists (Trospium Chloride and Darifenacin Hydrobromide) with one standard drug (Oxybutynin Chloride) for treatment of overactive bladder in individuals with spinal cord injury. |
| NCT00863551 ↗ | Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial | Completed | Allergan | Phase 4 | 2009-04-01 | This study evaluates the penetration through the blood-brain-barrier of trospium chloride at plasma steady state (Day 10) in elderly subjects with overactive bladder symptoms. Trospium levels in cerebrospinal fluid (CSF) and peak and trough plasma levels will be measured. Baseline and day 10 post-dose neurocognitive testing will be compared using a reliable change index to assess if any study subject shows evidence of a clinically and statistically significant change in memory. |
| NCT00932022 ↗ | Trospium Chloride XR in Obese Female Patients With Overactive Bladder | Completed | Allergan | Phase 4 | 2009-07-01 | This study evaluated the effectiveness of trospium chloride extended release (XR) in obese female patients with overactive bladder (OAB). Patients received either placebo and trospium chloride XR or placebo only. The study assessed the change from baseline in urinary frequency, urgency, and incontinence for trospium chloride XR versus a placebo-pill. The study was 14 weeks in duration. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Trospium Chloride
Condition Name
Clinical Trial Locations for Trospium Chloride
Trials by Country
Clinical Trial Progress for Trospium Chloride
Clinical Trial Phase
Clinical Trial Sponsors for Trospium Chloride
Sponsor Name
